Esther Ellen Freeman, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoma, Kaposi | 15 | 2022 | 370 | 6.740 |
Why?
|
Dermatology | 19 | 2023 | 872 | 6.060 |
Why?
|
Skin Diseases | 14 | 2023 | 1065 | 5.350 |
Why?
|
Chilblains | 5 | 2022 | 14 | 3.350 |
Why?
|
Registries | 15 | 2022 | 8089 | 1.630 |
Why?
|
HIV Infections | 26 | 2023 | 16718 | 1.520 |
Why?
|
Drug Eruptions | 2 | 2021 | 297 | 1.260 |
Why?
|
Coronavirus Infections | 6 | 2020 | 3133 | 1.090 |
Why?
|
Pneumonia, Viral | 6 | 2020 | 3240 | 1.080 |
Why?
|
Blister | 2 | 2023 | 86 | 0.990 |
Why?
|
Kenya | 8 | 2022 | 685 | 0.980 |
Why?
|
Acquired Immunodeficiency Syndrome | 3 | 2023 | 2232 | 0.960 |
Why?
|
Herpes Genitalis | 4 | 2008 | 141 | 0.900 |
Why?
|
Vaccines | 2 | 2021 | 822 | 0.860 |
Why?
|
Lymphangitis | 1 | 2022 | 12 | 0.850 |
Why?
|
Yaws | 1 | 2020 | 2 | 0.780 |
Why?
|
Surgical Equipment | 1 | 2021 | 57 | 0.780 |
Why?
|
Buruli Ulcer | 1 | 2020 | 7 | 0.770 |
Why?
|
International Cooperation | 4 | 2020 | 1420 | 0.770 |
Why?
|
Chickenpox | 1 | 2021 | 131 | 0.770 |
Why?
|
Elephantiasis, Filarial | 1 | 2020 | 29 | 0.760 |
Why?
|
Skin | 5 | 2023 | 4364 | 0.760 |
Why?
|
Onchocerciasis | 1 | 2020 | 24 | 0.760 |
Why?
|
Leprosy | 1 | 2020 | 124 | 0.740 |
Why?
|
Developing Countries | 4 | 2021 | 2815 | 0.730 |
Why?
|
Exanthema | 2 | 2022 | 501 | 0.730 |
Why?
|
Dermoscopy | 1 | 2020 | 56 | 0.710 |
Why?
|
Dermatologic Agents | 2 | 2024 | 278 | 0.700 |
Why?
|
Health Resources | 3 | 2020 | 911 | 0.700 |
Why?
|
Pemphigoid, Bullous | 1 | 2021 | 109 | 0.700 |
Why?
|
Herpesvirus 2, Human | 4 | 2008 | 189 | 0.700 |
Why?
|
Leishmaniasis, Cutaneous | 1 | 2020 | 124 | 0.680 |
Why?
|
Herpes Simplex | 2 | 2021 | 470 | 0.680 |
Why?
|
Herpes Zoster | 1 | 2021 | 264 | 0.670 |
Why?
|
Communicable Diseases, Emerging | 1 | 2020 | 157 | 0.630 |
Why?
|
Herpesvirus 8, Human | 1 | 2020 | 258 | 0.630 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2021 | 469 | 0.610 |
Why?
|
Microscopy, Confocal | 2 | 2020 | 1970 | 0.600 |
Why?
|
Urticaria | 3 | 2022 | 150 | 0.580 |
Why?
|
Policy Making | 1 | 2020 | 554 | 0.570 |
Why?
|
Research Support as Topic | 1 | 2020 | 705 | 0.550 |
Why?
|
Health Services Accessibility | 3 | 2023 | 5137 | 0.530 |
Why?
|
Publishing | 1 | 2023 | 833 | 0.530 |
Why?
|
Mentors | 1 | 2020 | 631 | 0.520 |
Why?
|
Humans | 90 | 2024 | 744343 | 0.520 |
Why?
|
Disease Outbreaks | 7 | 2023 | 1772 | 0.510 |
Why?
|
Community Health Services | 1 | 2020 | 650 | 0.490 |
Why?
|
Pandemics | 10 | 2021 | 8388 | 0.460 |
Why?
|
Bleomycin | 3 | 2022 | 512 | 0.420 |
Why?
|
Skin Neoplasms | 4 | 2021 | 5686 | 0.410 |
Why?
|
Point-of-Care Systems | 1 | 2020 | 1177 | 0.400 |
Why?
|
Vincristine | 3 | 2022 | 1039 | 0.390 |
Why?
|
Keratosis, Actinic | 2 | 2021 | 74 | 0.370 |
Why?
|
Biopsy | 2 | 2021 | 6756 | 0.350 |
Why?
|
Herpes Simplex Virus Vaccines | 1 | 2008 | 18 | 0.330 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2014 | 1873 | 0.330 |
Why?
|
Sexual Behavior | 6 | 2012 | 2057 | 0.310 |
Why?
|
Africa South of the Sahara | 7 | 2020 | 724 | 0.300 |
Why?
|
Etoposide | 2 | 2022 | 641 | 0.300 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 7279 | 0.280 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2020 | 657 | 0.260 |
Why?
|
Vaccination | 6 | 2022 | 3278 | 0.260 |
Why?
|
Primary Health Care | 3 | 2020 | 4558 | 0.250 |
Why?
|
Anti-HIV Agents | 2 | 2019 | 4256 | 0.240 |
Why?
|
Disease Susceptibility | 2 | 2021 | 1782 | 0.240 |
Why?
|
Circumcision, Male | 3 | 2011 | 150 | 0.230 |
Why?
|
Marriage | 1 | 2004 | 339 | 0.220 |
Why?
|
Severity of Illness Index | 4 | 2021 | 15540 | 0.210 |
Why?
|
Delivery of Health Care | 2 | 2017 | 5319 | 0.210 |
Why?
|
Equipment Design | 2 | 2020 | 3582 | 0.210 |
Why?
|
Academies and Institutes | 2 | 2023 | 317 | 0.200 |
Why?
|
Paclitaxel | 2 | 2022 | 1708 | 0.200 |
Why?
|
Adult | 25 | 2024 | 214055 | 0.190 |
Why?
|
Angioedema | 1 | 2022 | 187 | 0.190 |
Why?
|
Immunophilins | 1 | 2000 | 20 | 0.190 |
Why?
|
Herpesvirus 3, Human | 1 | 2021 | 204 | 0.180 |
Why?
|
Transients and Migrants | 1 | 2023 | 155 | 0.180 |
Why?
|
Consumer Advocacy | 1 | 2020 | 81 | 0.180 |
Why?
|
Authorship | 1 | 2023 | 271 | 0.180 |
Why?
|
Immunization, Secondary | 1 | 2022 | 340 | 0.180 |
Why?
|
Uganda | 2 | 2021 | 1243 | 0.180 |
Why?
|
Disease Progression | 3 | 2023 | 13284 | 0.180 |
Why?
|
Microbiological Techniques | 1 | 2020 | 102 | 0.180 |
Why?
|
Incidence | 7 | 2020 | 20947 | 0.170 |
Why?
|
Acne Vulgaris | 1 | 2024 | 302 | 0.170 |
Why?
|
Societies, Medical | 2 | 2022 | 3743 | 0.170 |
Why?
|
Administration, Cutaneous | 1 | 2021 | 711 | 0.170 |
Why?
|
Delayed Diagnosis | 1 | 2022 | 441 | 0.160 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2020 | 323 | 0.160 |
Why?
|
United States | 8 | 2023 | 69872 | 0.160 |
Why?
|
Ventilators, Mechanical | 1 | 2020 | 292 | 0.160 |
Why?
|
Photochemotherapy | 2 | 2021 | 807 | 0.160 |
Why?
|
Biomedical Technology | 1 | 2020 | 220 | 0.160 |
Why?
|
Simplexvirus | 1 | 2021 | 802 | 0.150 |
Why?
|
Prevalence | 7 | 2021 | 15226 | 0.150 |
Why?
|
Community Networks | 1 | 2019 | 203 | 0.150 |
Why?
|
Interferon-alpha | 1 | 2022 | 895 | 0.150 |
Why?
|
Doxorubicin | 2 | 2014 | 2234 | 0.150 |
Why?
|
Retinal Ganglion Cells | 2 | 2000 | 770 | 0.150 |
Why?
|
Sexually Transmitted Diseases | 3 | 2008 | 624 | 0.150 |
Why?
|
Cicatrix | 1 | 2023 | 764 | 0.150 |
Why?
|
Qualitative Research | 2 | 2023 | 2682 | 0.150 |
Why?
|
Male | 26 | 2021 | 350118 | 0.140 |
Why?
|
Middle Aged | 15 | 2021 | 213383 | 0.140 |
Why?
|
Optic Nerve | 1 | 2000 | 554 | 0.140 |
Why?
|
Foot | 1 | 2020 | 527 | 0.140 |
Why?
|
Urban Health | 4 | 2007 | 547 | 0.140 |
Why?
|
Tacrolimus | 1 | 2000 | 743 | 0.140 |
Why?
|
Standard of Care | 1 | 2020 | 564 | 0.140 |
Why?
|
Female | 23 | 2023 | 380194 | 0.130 |
Why?
|
Health Facilities | 1 | 2021 | 573 | 0.130 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2020 | 602 | 0.130 |
Why?
|
Young Adult | 5 | 2021 | 56430 | 0.130 |
Why?
|
Viral Vaccines | 1 | 2021 | 636 | 0.130 |
Why?
|
Selection, Genetic | 1 | 2020 | 914 | 0.130 |
Why?
|
Awareness | 1 | 2019 | 640 | 0.130 |
Why?
|
Interdisciplinary Communication | 1 | 2021 | 950 | 0.130 |
Why?
|
Africa | 3 | 2022 | 673 | 0.130 |
Why?
|
Adolescent | 13 | 2024 | 85781 | 0.130 |
Why?
|
Hand | 1 | 2020 | 884 | 0.120 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 738 | 0.120 |
Why?
|
RNA, Messenger | 4 | 2022 | 13033 | 0.120 |
Why?
|
Drug Therapy, Combination | 2 | 2014 | 6489 | 0.120 |
Why?
|
Immune Reconstitution Inflammatory Syndrome | 1 | 2014 | 66 | 0.120 |
Why?
|
Feasibility Studies | 2 | 2021 | 5078 | 0.120 |
Why?
|
Body Height | 1 | 2020 | 1577 | 0.110 |
Why?
|
Hypersensitivity | 1 | 2022 | 1102 | 0.110 |
Why?
|
Time Factors | 4 | 2020 | 40075 | 0.110 |
Why?
|
Psoriasis | 1 | 2020 | 898 | 0.110 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2020 | 941 | 0.100 |
Why?
|
Cost-Benefit Analysis | 3 | 2022 | 5391 | 0.100 |
Why?
|
Stochastic Processes | 3 | 2008 | 344 | 0.100 |
Why?
|
Epidemics | 1 | 2017 | 523 | 0.100 |
Why?
|
Tretinoin | 1 | 2014 | 517 | 0.100 |
Why?
|
Malawi | 1 | 2012 | 282 | 0.100 |
Why?
|
Biomedical Research | 2 | 2020 | 3309 | 0.100 |
Why?
|
Antineoplastic Agents | 1 | 2014 | 13695 | 0.100 |
Why?
|
Consensus | 1 | 2020 | 2959 | 0.100 |
Why?
|
Liposomes | 1 | 2014 | 759 | 0.100 |
Why?
|
Mutation, Missense | 1 | 2020 | 2564 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2021 | 2759 | 0.090 |
Why?
|
Cross-Sectional Studies | 6 | 2023 | 25043 | 0.090 |
Why?
|
Disease Management | 1 | 2021 | 2459 | 0.090 |
Why?
|
Review Literature as Topic | 1 | 2012 | 336 | 0.090 |
Why?
|
Tuberculosis | 1 | 2023 | 1912 | 0.090 |
Why?
|
Longitudinal Studies | 2 | 2022 | 13989 | 0.090 |
Why?
|
World Health Organization | 1 | 2014 | 1318 | 0.080 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3158 | 0.080 |
Why?
|
Risk-Taking | 2 | 2011 | 986 | 0.080 |
Why?
|
Polyethylene Glycols | 1 | 2014 | 1182 | 0.080 |
Why?
|
Evidence-Based Medicine | 1 | 2020 | 3610 | 0.080 |
Why?
|
Sexual Partners | 1 | 2012 | 730 | 0.080 |
Why?
|
Meta-Analysis as Topic | 1 | 2012 | 1344 | 0.080 |
Why?
|
HIV Seropositivity | 3 | 2004 | 971 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2014 | 9959 | 0.070 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2019 | 2104 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2000 | 4149 | 0.070 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11031 | 0.070 |
Why?
|
Risk Factors | 6 | 2021 | 72290 | 0.070 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11524 | 0.070 |
Why?
|
Fluorouracil | 2 | 2021 | 1619 | 0.070 |
Why?
|
Quality Improvement | 1 | 2020 | 3749 | 0.060 |
Why?
|
Extramarital Relations | 1 | 2004 | 6 | 0.060 |
Why?
|
Benin | 1 | 2004 | 12 | 0.060 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 12959 | 0.060 |
Why?
|
Cameroon | 1 | 2004 | 71 | 0.060 |
Why?
|
Benzoyl Peroxide | 1 | 2024 | 18 | 0.060 |
Why?
|
Zambia | 1 | 2004 | 261 | 0.060 |
Why?
|
Malta | 1 | 2023 | 6 | 0.060 |
Why?
|
Retinoids | 1 | 2024 | 101 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2019 | 7913 | 0.060 |
Why?
|
Isotretinoin | 1 | 2024 | 114 | 0.060 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2020 | 8949 | 0.060 |
Why?
|
Monkeypox virus | 1 | 2022 | 48 | 0.050 |
Why?
|
Age Factors | 3 | 2020 | 18370 | 0.050 |
Why?
|
Health Policy | 1 | 2014 | 2661 | 0.050 |
Why?
|
Rural Population | 1 | 2012 | 2210 | 0.050 |
Why?
|
Hyperventilation | 1 | 2001 | 81 | 0.050 |
Why?
|
Family Practice | 1 | 2004 | 516 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12354 | 0.050 |
Why?
|
Hospitalization | 1 | 2020 | 10262 | 0.050 |
Why?
|
Diclofenac | 1 | 2021 | 71 | 0.050 |
Why?
|
Nails | 1 | 2022 | 292 | 0.050 |
Why?
|
HIV-1 | 2 | 2008 | 6939 | 0.050 |
Why?
|
Microfibrils | 1 | 2020 | 17 | 0.050 |
Why?
|
Indians, South American | 1 | 2020 | 36 | 0.050 |
Why?
|
Chlamydia Infections | 1 | 2004 | 365 | 0.050 |
Why?
|
Nerve Crush | 1 | 2000 | 78 | 0.050 |
Why?
|
Heredity | 1 | 2020 | 154 | 0.040 |
Why?
|
Sex Factors | 2 | 2020 | 10397 | 0.040 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2000 | 428 | 0.040 |
Why?
|
Hair | 1 | 2022 | 483 | 0.040 |
Why?
|
Advisory Committees | 1 | 2023 | 775 | 0.040 |
Why?
|
Prognosis | 1 | 2020 | 29063 | 0.040 |
Why?
|
Tacrolimus Binding Proteins | 1 | 2000 | 195 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12245 | 0.040 |
Why?
|
Immunity, Humoral | 1 | 2022 | 598 | 0.040 |
Why?
|
Nigeria | 1 | 2020 | 733 | 0.040 |
Why?
|
Peru | 1 | 2020 | 881 | 0.040 |
Why?
|
Geographic Information Systems | 1 | 2019 | 281 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2007 | 14722 | 0.040 |
Why?
|
Botswana | 1 | 2020 | 1040 | 0.040 |
Why?
|
Faculty | 1 | 2020 | 386 | 0.040 |
Why?
|
Lost to Follow-Up | 1 | 2017 | 105 | 0.040 |
Why?
|
Cryosurgery | 1 | 2021 | 453 | 0.030 |
Why?
|
Rats, Wistar | 1 | 2000 | 1901 | 0.030 |
Why?
|
Lidocaine | 1 | 1999 | 544 | 0.030 |
Why?
|
Cell Count | 1 | 2000 | 1856 | 0.030 |
Why?
|
Public Opinion | 1 | 2019 | 477 | 0.030 |
Why?
|
DNA Primers | 1 | 2000 | 2892 | 0.030 |
Why?
|
Homosexuality | 2 | 1992 | 262 | 0.030 |
Why?
|
Follow-Up Studies | 1 | 2016 | 39050 | 0.030 |
Why?
|
Gene Frequency | 1 | 2020 | 3588 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2019 | 63114 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 4751 | 0.030 |
Why?
|
Blotting, Western | 1 | 2000 | 5179 | 0.030 |
Why?
|
Information Dissemination | 1 | 2019 | 1099 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4560 | 0.020 |
Why?
|
Leadership | 1 | 2019 | 1357 | 0.020 |
Why?
|
Bisexuality | 1 | 1992 | 270 | 0.020 |
Why?
|
Self Care | 2 | 1992 | 786 | 0.020 |
Why?
|
Age Distribution | 2 | 2008 | 2902 | 0.020 |
Why?
|
Public Health | 1 | 2022 | 2603 | 0.020 |
Why?
|
Africa, Eastern | 1 | 2007 | 71 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2020 | 3528 | 0.020 |
Why?
|
Health Promotion | 1 | 2019 | 2205 | 0.020 |
Why?
|
Aged | 4 | 2019 | 163280 | 0.020 |
Why?
|
Pilot Projects | 1 | 2020 | 8324 | 0.020 |
Why?
|
Africa, Western | 1 | 2007 | 154 | 0.020 |
Why?
|
Rats | 2 | 2000 | 24260 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2024 | 7181 | 0.020 |
Why?
|
Research Design | 2 | 2019 | 5987 | 0.020 |
Why?
|
Venereology | 1 | 2004 | 3 | 0.020 |
Why?
|
Chronic Disease | 1 | 2019 | 9146 | 0.020 |
Why?
|
Urban Population | 1 | 2011 | 2021 | 0.010 |
Why?
|
England | 1 | 2004 | 522 | 0.010 |
Why?
|
Disease Transmission, Infectious | 1 | 2008 | 547 | 0.010 |
Why?
|
Rural Health | 1 | 2004 | 305 | 0.010 |
Why?
|
Chlamydia trachomatis | 1 | 2004 | 246 | 0.010 |
Why?
|
Asthma | 1 | 2001 | 6011 | 0.010 |
Why?
|
Patient Education as Topic | 1 | 1992 | 2278 | 0.010 |
Why?
|
Pregnancy | 1 | 2023 | 29144 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2020 | 12261 | 0.010 |
Why?
|
Counseling | 1 | 2008 | 1523 | 0.010 |
Why?
|
Nimodipine | 1 | 1999 | 55 | 0.010 |
Why?
|
Focus Groups | 1 | 2004 | 1321 | 0.010 |
Why?
|
Dizocilpine Maleate | 1 | 1999 | 176 | 0.010 |
Why?
|
Rats, Long-Evans | 1 | 1999 | 387 | 0.010 |
Why?
|
Patient Acceptance of Health Care | 1 | 1992 | 3022 | 0.010 |
Why?
|
Computer Simulation | 1 | 2011 | 6196 | 0.010 |
Why?
|
Retrospective Studies | 3 | 2022 | 77449 | 0.010 |
Why?
|
Models, Statistical | 1 | 2011 | 5102 | 0.010 |
Why?
|
Sex Distribution | 1 | 2001 | 2297 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2008 | 3589 | 0.010 |
Why?
|
Health Care Costs | 1 | 2008 | 3209 | 0.010 |
Why?
|
Child | 1 | 2023 | 77709 | 0.010 |
Why?
|
Syndrome | 1 | 2001 | 3251 | 0.010 |
Why?
|
Neuroprotective Agents | 1 | 1999 | 941 | 0.010 |
Why?
|
San Francisco | 1 | 1992 | 159 | 0.010 |
Why?
|
Clinical Nursing Research | 1 | 1991 | 16 | 0.010 |
Why?
|
Animals | 2 | 2000 | 168757 | 0.010 |
Why?
|
Internal-External Control | 1 | 1991 | 363 | 0.010 |
Why?
|
Cell Survival | 1 | 1999 | 5882 | 0.010 |
Why?
|
Algorithms | 1 | 2008 | 13881 | 0.000 |
Why?
|
Affect | 1 | 1991 | 1476 | 0.000 |
Why?
|
Health Behavior | 1 | 1992 | 2636 | 0.000 |
Why?
|
Quality of Life | 1 | 1991 | 12804 | 0.000 |
Why?
|